Jpmorgan Chase & CO Precigen, Inc. Transaction History
Jpmorgan Chase & CO
- $1.22 Trillion
- Q3 2024
A detailed history of Jpmorgan Chase & CO transactions in Precigen, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 884,275 shares of PGEN stock, worth $742,791. This represents 0.0% of its overall portfolio holdings.
Number of Shares
884,275
Previous 1,078,789
18.03%
Holding current value
$742,791
Previous $1.7 Million
50.7%
% of portfolio
0.0%
Previous 0.0%
Shares
14 transactions
Others Institutions Holding PGEN
# of Institutions
143Shares Held
159MCall Options Held
232KPut Options Held
69K-
Third Security, LLC83.5MShares$70.1 Million73.5% of portfolio
-
Patient Capital Management, LLC Baltimore, MD17.9MShares$15.1 Million0.92% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA10.9MShares$9.13 Million0.02% of portfolio
-
Black Rock Inc. New York, NY10.2MShares$8.61 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.33MShares$7 Million0.0% of portfolio
About PRECIGEN, INC.
- Ticker PGEN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 208,150,000
- Market Cap $175M
- Description
- Precigen, Inc. discovers and develops the next generation of gene and cellular therapies in the United States. It also provides disease-modifying therapeutics; genetically engineered swine for regenerative medicine applications; and reproductive and embryo transfer technologies. In addition, the company offers UltraVector platform that incorpora...